Air Cleaners for Children and Adolescents With Asthma and Dog Allergy

Summary

The purpose is to find out if Icleen IQAir, HEPA-filter air cleaners with high capacity and pre-set speed functions, have a beneficial effect on patients with asthma and allergy to dogs.

Air cleaners will be installed in the bedrooms and living rooms in the homes of children and adolescents aged 8-17 years at the study entry, with allergy to dogs, but not to house dust mites.

The investigators will look upon the significance of this study, and of a previous study with a similar design and the same main parameters to find out if this trial supports the results of the first trial by the same project leader, or makes it likely that the seemingly beneficial effects of the first study occurred by chance.

Main parameters:

* hyperventilation cold air challenge test

Supportive parameters:

* serum ECP
* symptom scores

The trial will be a parallel, double blind placebo controlled one.

Conditions

• Asthma
• Allergy

Interventions

DEVICE

IQAir Allergen 100 Air cleaners

Two air cleaners are installed in the patient's room, one in his bedroom, and one in the living room. The cleaners can be run at 5 different speeds: Speed 1 filtrates 60m3 of air per hour, speed 2 filtrates 90 m3 per hour, speed 3 filtrates 130 m3 per hour, speed 4 filtrates 240 m3 per hour, and speed 5 filtrates 380 m3 per hour. A timer-on period can be pre-set for every day of the week, but the cleaner can be run even in the timer-off period, at a speed pre-set and different from the timer-on period. Different timer-on off periods cannot be selected for different days, but the different days of the week can be pre-set to apply timer-on periods or not.

Sponsors & Collaborators

• Incen AG

  collaborator INDUSTRY

• Sykehuset Innlandet HF

  lead OTHER

Principal Investigators

• Leif B. Rolfsjord, M.D. · Sykehuset Innlandet HF

• Leiv Sandvik, PhD · Oslo Universitetssykehus Ulleval

• Ragnhild Halvorsen, M.D., Ph.D. · Oslo Universitetssykehus Rikshospitalet

• Sten Dreborg, M.D., Ph.D. · Alingsåsv. 11, S-443 35 Lerum, Sweden

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

TRIPLE

Model

PARALLEL

Eligibility

Min Age

8 Years

Max Age

17 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2005-09-30

Primary Completion

2006-02-28

Completion

2006-04-30

Countries

• Norway

Study Locations